MGF Research# MGF research originates primarily from the laboratory of Geoffrey Goldspink at University College London: Discovery and characterization : First described in the late 1990s as a mechanically sensitive IGF-1 splice variant in rabbit and human skeletal muscle Satellite cell activation : Demonstrated ability to activate quiescent satellite cells in culture, with evidence for IGF-1R-independent signaling Cardiac applications : Expression of IGF-1Ec documented in cardiac muscle following myocardial infarction, with preclinical evidence for cardioprotective effects Neuroprotection : MGF expression detected in brain tissue following ischemic injury, with preliminary evidence for neuronal survival effects Aging research : Impaired MGF upregulation documented in elderly subjects after exercise, suggesting a mechanism for age-related decline in regenerative capacity MGF remains entirely preclinical, with no human clinical trials

It has several far-reaching consequences like increased incidence of heart diseases, diabetes, depression, reduced quality of life and even death
In mid to late 2025, around 12.4% of US adults reported taking a GLP-1 medicine specifically for weight loss, up from 5.8% in February 2024, according to Gallup survey data of more than 15,000 adults
SGLT2 inhibitors have proven efficacy in slowing chronic kidney disease progression, reducing albuminuria, and decreasing risk of end-stage renal disease
Ideal candidates are those who havent achieved meaningful results with dieting, exercise alone, or non-medical weight-loss programs